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2Abstract 
Amyloid formation and neuroinflammation are major features of Alzheimer’s disease pathology. 
Proinflammatory mediator S100A9 was shown to act as a link between the amyloid and neuroin-
flammatory cascades in Alzheimer’s disease, leading together with Aβ to plaque formation, neu-
ronal loss and memory impairment. In order to examine if S100A9 alone in its native and amy-
loid states can induce neuronal stress and memory impairment, we have administered S100A9 
species intranasally to aged mice. Single and sequential immunohistochemistry and passive 
avoidance behavioral test were conducted to evaluate the consequences. Administered S100A9 
species induced wide-spread cellular stress responses in cerebral structures, including frontal 
lobe, hippocampus and cerebellum. These were manifested by increased levels of S100A9, Bax 
and to lesser extent activated caspase-3 immunopositive cells. Upon administration of S100A9 
fibrils the amyloid oligomerization was observed in the brain tissues, which can further exacer-
bate cellular stress. The cellular stress responses correlated with significantly increased training 
and decreased retention latencies measured in the passive avoidance test for the S100A9 treated 
animal groups. Remarkably, the effect size in the behavioral tests was moderate already in the 
group treated with native S100A9, while the effect sizes were large in the groups administered 
S100A9 amyloid oligomers or fibrils. The findings demonstrate the brain susceptibility to neuro-
toxic damage of S100A9 species leading to behavioral and memory impairments. Intranasal ad-
ministration of S100A9 species proved to be an effective method to study amyloid induced brain 
dysfunctions, and S100A9 itself may be postulated as a target to allay early stage neurodegenera-
tive and neuroinflammatory processes. 
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3Introduction 
Ordered protein aggregation, known as amyloid formation, has recently emerged as a universal 
phenomenon involved in a number of human pathologies including Alzheimer's and Parkinson's 
diseases, diabetes mellitus and others.
1
 Amyloid is characterized by a generic structure of cross-
β-sheet in its core, and this structure is common to all amyloid fibrils formed by various structur-
ally unrelated polypeptides both in vivo and in vitro. Amyloids can be deposited in various tis-
sues and organs causing damage due to their hazardous accumulation and cytotoxicity of small 
self-assembled entities known as amyloid oligomers.
2
 It has been demonstrated that a number of
neurodegenerative amyloid illnesses share links with age-dependent changes in the body. The 
growing elderly population correlates with significant increase in numbers of patients suffering 
from neurodegenerative conditions and ultimately with increasing social and health care costs. 
By statistical estimate in 2050 a population of more than 100 million people worldwide will suf-
fer from Alzheimer’s disease and that will triple the current number. 
One of the hallmarks of Alzheimer’s disease is Aβ peptide amyloid accumulation. How-
ever, increasing evidence has demonstrated that inflammation may also play a crucial role in 
triggering and promoting neurodegeneration.
3, 4
 Chronic and acute inflammation associated with
traumatic brain injury may fulfill this role and is the subjects of intense scrutiny.
5
 Epidemiologi-
cal studies have demonstrated that non-steroidal anti-inflammatory drugs markedly reduce the 
age-related prevalence of Alzheimer’s disease.
6
 Experimental studies have shown that these
drugs can slow down amyloid deposition in animal models by mechanisms that still remain poor-
ly understood.
7
 Inflammation in Alzheimer’s disease is supported by a sharp induction of in-
flammatory mediators within the brain tissues affected by disease.
8
 In general, during Aβ amy-
loid plaque formation microglia become activated and recruited to the deposition sites causing 
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4Among the numerous inflammatory factors and cytokines associated with neuroinflam-
mation here we focus specifically on S100A9 protein, possessing not only pro-inflammatory but 
also amyloidogenic properties.
13, 14
 It belongs to the family of S100 proteins, which are charac-
terized by structural homology, ability to bind calcium ions and perform signaling functions in 
numerous inflammation-related conditions, including cancers, autoimmune diseases and neuro-
degeneration.
15
 Widespread production of S100A9 has been reported in the brain in malaria,
16
cerebral ischemia 
17
 and traumatic brain injury,
18
 where it may initiate sustainable inflammatory
responses and perform cytokine-like functions, affecting inflammatory responses of other cells. 
Recently, we have demonstrated a critical involvement of S100A9 protein in the amyloid-
neuroinflammatory cascade in Alzheimer’s disease, where S100A9 exacerbates the aggregation 
of Aβ peptide.
14
 It has also been shown that in an Alzheimer’s disease transgenic mouse model
S100A9 expression can be induced by Aβ peptide, while S100A9 knockdown attenuated 
memory impairment and reduced amyloid plaque burden.
19
 Similarly, in transgenic APP mice
amyloid aggregation of another protein from the S100 family – S100A8 has been shown to pre-
cede Aβ plaque formation and the positive feedback was involved for both S100A8 and Aβ pro-
duction.
20
 Furthermore, in vitro amyloid fibrillation was found to be a property of S100A6 pro-
tein from the same family, which can promote amyloid aggregation of superoxide dismutase-1 
involved in amyotrophic lateral sclerosis pathology.
21
 The amyloid propensity of the S100 pro-
tein family is related to the presence of intrinsically disordered sequences in their primary struc-
microgliosis,
9
 although Alzheimer’s- ype plaques can also be sustained in the absence of micro- 
glia.
10
 The activated microglia secrete an array of pro- and anti-inflammatory mediators, which
may contribute to changes in neuronal calcium homeostasis and further accelerate neuritic and 
synaptic dysfunction.
11, 12
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5Previous studies have shown that amyloid species and other proteinaceous compounds 
can be delivered to the brain via the nasal route, thus bypassing the blood-brain barrier. The nasal 
vector has proved to be an efficient route for targeting the brain and evaluating amyloid induced 
central nervous system and related behavioral dysfunctions following Aβ peptide administration 
in rats
26
 as well as administration of S100A9 and α-synuclein amyloid species in mice.
27-29
 Nasal
delivery to the brain has also been demonstrated for other peptides and proteins such as glyco-
gen, vasopressin, insulin-like growth factor and insulin.
30-32
In this study, we administered S100A9 amyloid species via intranasal route in aged mice 
in order to elucidate their effect on cellular responses and amyloid seeding in the brain tissues in 
conjunction with behavioral impairment comparable to Alzheimer’s-like pathology. Alzheimer’s 
and Alzheimer’s like pathology have been studied intensively using both non-transgenic and 
transgenic mouse models, which may feature some, but not all Alzheimer’s  pathologies. A wide 
range of transgenic Alzheimer’s models were generated to monitor disease progression.
19, 33-35
However, usage of the transgenic mice could be time-consuming and often uneconomical since it 
takes months for the animals to develop Aβ plaques and even longer to show Aβ-induced synap-
tic or behavioral abnormalities.
33, 36
 In addition the amyloid fibrils deposited in the brain of the
transgenic mice maybe chemically and morphologically distinct from those accumulated in the 
Alzheimer’s disease brain.
37
 Therefore there are distinct advantages to use non-transgenic mouse
ture, which can be exposed upon loss of structural protection in the native tertiary or quaternary 
folds and become accessible to amyloid-competent conformations.
22
 The amyloid formation of
S100A9 can be promoted by a general rise of its concentration occurring during inflammation in 
the tissue, as reported in Alzheimer’s disease
14
 and the aging prostate,
23
 as well as by S100A9 
overexpression in a cell model 
24
 or in concentrated solutions in vitro.
14, 25
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6models based on the direct active compound administration, such as injection of Aβ or scopola- 
mine.
38, 39
 These models may mimic some symptomatic outcomes, such as behavioral abnormali-
 ies or exhibit to different degree Aβ related molecular and cellular pathology. The present ex- 
periments were carried out in order to shed light on the role of S100A9 alone in inducing Alz- 
heimer’s-like tissue and behavioral outcomes in contrast to Aβ peptide, which has been primarily 
implicated in Alzheimer’s disease pathology. 
Results 
Characterization of S100A9 amyloid oligomer and fibrillar species. 
The samples containing S100A9 amyloid oligomers and fibrils were incubated under conditions 
described in Materials and Methods and collected after 2 h and 24 h, respectively. S100A9 amy- 
loid oligomers were characterized by a round-shaped morphology and some of them were 
aligned into short stretched protofilaments as assessed by atomic force microscopy (AFM) imag- 
ing (Fig. 1A). S100A9 amyloid fibrils were flexible and coiled, reaching a few hundred nanome- 
 ers in length (Fig. 1B). The presence of some round-shaped oligomers among the fibrillar spe- 
cies could not be excluded, as evident in AFM image (Fig. 1B), that could occur due to fibril 
breaking and amyloid material recycling.
40, 41
 However, the majority of species in this sample
were fibrillar. The amyloid formation of S100A9 was corroborated also by increasing thioflavin-
T fluorescence, occurring when the dye binds specifically to the amyloid species (Fig. 1C). The 
thioflavin-T fluorescence signal after 2 h incubation, corresponding to the formation of amyloid 
oligomers, was by ca. 10 times lower than after 24 h, when thioflavin-T signal has reached plat- 
eau level and amyloid fibrils were formed (Fig. 1C). 
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Immunohistochemical analysis of mouse brain tissues.  
After intranasal administration of S100A9 species, the location of S100A9 antigens in the mouse 
brain tissues, including the frontal lobe, hippocampus and cerebellum areas, was analyzed by us-
ing immunohistochemistry (Fig. 2). Four groups of animals were subjected to dosing protocol as 
described in Materials and Methods. In all studied brain tissues cell nuclei were contrasted by 
hematoxylin staining. Even in control group some S100A9 immunopositive cells were present in 
all studied brain regions, which may be related to their age (12-month-old) and age-related tissue 
changes
19
 (Fig. 2A-F). In general, S100A9 immunopositive cells were found in both S100A9
treated and control animals and they were located within the III-V cell layers of the frontal lobe, 
morphologically resembling pyramidal, grain and ganglion neurons (Fig. 2B, H, N, T); in the 
pyramidal layer of the archicortex Ammon’s horn of the hippocampus (Fig. 2D, J, P, V) and in 
the cerebellum corresponding to Purkinje cells (Fig. 2F, L, R, X). 
Sequential immunohistochemistry with S100A9 and NeuN antibodies was conducted on 
the same brain tissues of mouse treated with S100A9 amyloid fibrils in order to examine if 
S100A9 is present in neuronal cells (Fig. S1). We have observed clear co-localization of S100A9 
and NueN staining (overlapping of immunostaining patterns) as shown in representative images 
of neuronal cells in the frontal lobe and the same observation were made in the hippocampus and 
cerebellum, confirming that S100A9 is indeed expressed by neuronal cells. The same im-
munostaining pattern was observed in other groups of S100A9 treated mice.  
Immunohistochemistry with Bax (Fig. 3) and activated caspase-3 (Fig. S2) antibodies 
was conducted in a similar set up and revealed similar patterns in all studied brain structures as 
the immunostaining with S100A9 antibodies (Fig. 2). This indicates that pro-apoptotic markers 
were also induced in the brain tissues immunopositive for S100A9. Specifically, the co-
localization of S100A9 and activated caspase-3 immunostaining patterns was observed in all 
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8three studied brain areas of mouse treated with S100A9 amyloid fibrils by using sequential im-
munohistochemistry with corresponding antibodies (Fig. S3), indicating that both antigens may 
be produced within the same cells. 
Quantification of immunopositive cells in mouse brain tissues.  
In order to estimate the relative effect of administered S100A9 amyloid species on the cell stress 
in the mouse brain tissues compared to controls, the cells immunopositive for S100A9, Bax and 
activated caspase-3 were counted in six randomly selected areas in each brain structure. The 
counts are presented by box-plots, where each point corresponds to an average of the counts 
from six random areas (Fig. 4). The number of S100A9-immunopositive cells significantly in-
creased in the frontal lobe and hippocampus upon administration of all S100A9 species, contain-
ing native protein, oligomers and fibrils, respectively (Fig. 4A, B). The largest increase of 
S100A9 immunopositive cells was observed in these tissues upon administration of S100A9 oli-
gomeric species with the increase of median values by two and three folds in the frontal lobe and 
hippocampus, respectively. In the cerebellum, the amounts of S100A9 immunopositive cells in 
all treated groups were generally lower compared to those in the frontal lobe and hippocampus, 
however these levels were still significantly higher than in controls (Fig. 4A-C). 
Significant increase in the numbers of Bax immunopositive cells was observed in the 
frontal lobe of mice treated with all S100A9 species compared to controls with the largest in-
crease corresponding to the group administered amyloid oligomers (Fig. 4D). In the hippocam-
pus, the most pronounced increase in the level of Bax immunopositive cells was observed in 
mice administered S100A9 oligomers and fibrils (Fig. 4E). Upon administration of the native 
and oligomeric S100A9 species the amounts of Bax positive cells in the cerebellum were very 
close to those in control group, except significant increase in the group treated with S100A9 fi-
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9brils (Fig. 4F). The changes in the S100A9 and Bax immunopositive cell levels in the mouse 
brain tissues broadly resemble each other (Fig. 4). This suggests that induction of S100A9 and 
Bax occurred via similar mechanisms and the frontal lobe is the most affected by the administra-
tion of S100A9 species. 
The highest levels of activated caspase-3 immunopositive cells were observed in the 
frontal lobe and hippocampus of mice treated with native S100A9 compared to controls (Fig. 4G, 
H). The administration of S100A9 oligomers also led to significant increase of the number of 
activated caspase-3 immunopositive cells both in the frontal lobes and hippocampus (Fig. 4G, 
H), however the S100A9 fibrillar species did not induce activated caspase-3 either in the frontal 
lobe or hippocampus. In the cerebellum, the number of activated caspase-3 positive cells in-
creased in the group administered oligomeric S100A9, while in other groups those levels re-
mained close to controls (Fig. 4I). Thus, the pattern of activated caspase-3 induction in the 
mouse brain areas deviates from those of S100A9 and Bax. However, in all treated animal 
groups the frontal lobe is the most susceptible region to the administration of S100A9 species as 
shown by a drastic rise of the levels of S100A9, Bax and activated caspase-3 immunopositive 
cells, while the cerebellum is the least susceptible area (Fig. 4).
Localization of Aβ and amyloid oligomers in mouse brain tissues. 
Sequential immunohistochemistry with Aβ, S100A9 and oligomer specific A11 antibodies was 
conducted to examine the localization of these antigens relative to each other in the mouse brain 
tissues after administration the samples containing S100A9 fibrils (Fig. 5). We have observed 
S100A9 positive cells in all studied brain areas as indicated above (Figs. 2, 4). The deposits of 
Aβ peptide were found only in the blood vessels in the frontal lobe, hippocampus and cerebellum 
of the S100A9 treated mice (Fig. 5A, E, I) as well as in control animals (Fig. S4A, D, G). How-
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10
ever, S100A9 was not found in these blood vessels, but only in neuronal cells in the surrounding 
tissues, indicating that S100A9 and Aβ are not co-localized. 
The A11 immunopositive staining was observed in all studied brain areas in the group of 
mice treated with the S100A9 fibrillar species compared to controls (Fig. 5B, F, J). The round-
shaped inclusions of proteinaceous material reactive with A11 antibodies were well spread in the 
brain tissues of S100A9 treated animals, while the brain structures of control group were charac-
terized by complete lack of A11 antibody reactivity (Fig. S4B, E, H). However, neither in the 
frontal lobe nor in other studied brain regions the immunostaining patterns of S100A9 and A11 
were fully overlapped as well as there was no overlapping of A11 immunostaining with Aβ pep-
tide accumulations found in blood vessels (Fig. 5, S4). Since S100A9, but not Aβ, was shown to 
be produced by neuronal cells (Fig. S1), this suggests that in some cells or extracellularly 
S100A9 may be present at the levels exceeding critical concentration and sufficient for sponta-
neous self-assembly into amyloid oligomers, especially if this process is further exacerbated by 
administered amyloid species.
25, 42
 Clearly, Aβ was not a leading amyloidogenic peptide aggre-
gating in the mouse brain tissues, as it was found only in the blood vessels (Fig. 5A, E, I). Its 
presence in the blood vessels is more likely related to mouse age,
19, 43
 since the same pattern was
observed both in animals treated with S100A9 fibrils and in controls.  
Mouse performance in passive avoidance test. 
Results of the passive avoidance test, to which all four animal groups were subjected, are pre-
sented by box-plots in Fig. 6. Remarkably, all mouse groups treated with S100A9 species 
showed statistically significant increase in training latencies (Fig. 6A) and decrease in retention 
latencies compared to controls (Fig. 6B). Furthermore, we have estimated the magnitude of the 
observed effect
44
 in addition to its statistical significance. We evaluated the effect size by using
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11
Cliff’s delta (δ) and its 95% confidence intervals (Fig. 6C).
45
 Cliff’s delta is defined to range
from -1 to 1, reflecting the extent to which one distribution tends to generally lie above or below 
another.
45
 We used here the following scale for the effect size: 0.1< δ<0.3 corresponded to a
small effect, 0.3< δ<0.5 – to medium and 0.5< δ<1.0 – to large effect, respectively.
46
 The effect
sizes for the training (0.48, 95% CI 0.11, 0.74) and retention (-0.46, 95% CI -0.08, -0.77) laten-
cies for the group treated with native S100A9 were medium. Importantly, the effect sizes for 
both latencies in the groups treated with S100A9 amyloid oligomers and fibrils were large. Spe-
cifically, the effect sizes for the training latencies in the groups treated with amyloid oligomers 
and fibrils were 0.9, 95% CI 0.56, 0.98 and 0.71, 95% CI 0.35, 0.87, respectively. The effect siz-
es for the retention latencies in the same groups were 0.73, 95% CI 0.38, 0.98 and 0.78, 95% CI 
0.52, 0.99, respectively. These clearly demonstrate that the animals treated with S100A9 species, 
especially amyloid oligomers and fibrils, displayed impediments both in training and subsequent 
memory retention, reflecting impairment of their fear-aggravated memory formation. 
Discussion 
The pro-inflammatory mediator S100A9 has been identified as an important contributor to Alz-
heimer’s disease pathology
47, 48
 and inflammation-dependent aging.
49
 Recently, we have demon-
strated that S100A9 serves as a critical link between the neuroinflammatory and amyloid cas-
cades in Alzheimer’s disease, since it acts both as a pro-inflammatory mediator involved in the 
damage associated molecular patterns and a highly amyloidogenic protein.
14
 In the latter capacity
S100A9 co-aggregates together with Aβ peptide into amyloid fibrils, leading to amyloid plaque 
formation in the brain tissues, while S100A9 amyloid oligomers exhibit cellular toxicity as 
demonstrated in in vitro experiments. Interestingly, in conjunction with Aβ peptide S100A9 can 
be used as a robust diagnostic marker of Alzheimer’s disease pathology already at a very early 
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stage of mild cognitive impairment,
50
 which further emphasizes its involvement in disease de-
velopment. Furthermore in the transgenic Tg2576 mouse model the knockdown of S100a9 ex-
pression had improved the cognition decline of Tg2576 mice as assessed by their performance in 
the water maze task and reduced their amyloid plaque burden.
19
 Similarly in transgenic model of
Alzheimer’s disease produced by cross-breeding the Tg2576 mouse with the S100A9 knockout 
mouse animals displayed an increased spatial reference memory in the Morris water maze and Y-
maze tasks as well as decreased Aβ neuropathology.
51
 These findings suggest that S100A9 in its
own right plays an essential role in development of Alzheimer’s pathology. Understanding 
S100A9 multifaceted properties and mechanisms of actions is still in its infancy, however this 
knowledge is critical since S100A9 can be used as a therapeutic target in Alzheimer’s disease 
treatment. 
By using non-invasive intranasal administration of S100A9 in its native and amyloid 
forms to aged mice, we have examined their effects on the cellular stress and apoptotic pathway 
initiation as well as on amyloid seeding in different cerebral structures relevant to fear aggregat-
ed memory formation. The pathological outcomes observed in the brain tissues were related to 
the symptomatic behavior of experimental animals manifested in the training and retention laten-
cy changes in the fear-aggravated passive avoidance memory test. 
It is noteworthy that repetitive 14-day administration of S100A9 native or amyloid spe-
cies incited substantial cellular stress in the frontal lobe and hippocampus, manifested in in-
creased amounts of the S100A9, Bax and to a lesser extent of activated caspase-3 immunoposi-
tive cells in these areas. The observed cellular responses to S100A9 species can be related both 
to (1) the signaling properties of native S100A9 able to activate RAGE and TLR-4 receptors and 
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13
elevate the intracellular level of pro-inflammatory cytokines
13, 52, 53
 and (2) the cytotoxic and
stress inducing properties of amyloid species.
14, 54
The S100A9 oligomeric samples were very potent inducers of intracellular S100A9 and 
Bax levels both in the frontal lobe and hippocampus (Figs. 2-4). In the hippocampus, the sample 
containing S100A9 amyloid fibrils produced an even more pronounced effect on Bax induction, 
which could be due to potential fibrillar fractionation and secondary seeding of amyloid oligo-
mers.
41
 Interestingly, it has been shown that RAGE activation may occur via binding of mono-
meric and fibrillary forms of Aβ and β-sheet fibril structures,
55, 56
 which does not exclude the
possibility that S100A9 amyloids, via their generic amyloid conformational epitope,
57
 can also
interact with RAGE, inducing activation of the signaling pathways. Moreover, it has been shown 
recently that S100A9 fibrils provide a priming signal to activate the NLRP3 inflammasome, 
which causes the release of proinflammatory cytokines such as IL-1B and IL-18.
58
 However, in
our experiments the most pronounced effect on intracellular activated caspase-3 induction was 
produced by native S100A9 in its proinflammatory mediator capacity. Notably, in the cerebellum 
the levels of S100A9, Bax and activated caspase-3 immunopositive cells were low in all treated 
and control mouse groups, indicating that this area was less susceptible to the effects incited by 
intranasal S100A9 administration. Importantly, S100A9 was detected specifically in neuronal 
cells in all studied brain structures as revealed by co-localization of S100A9 and NeuN im-
munostaining in sequential immunohistochemistry experiments (Fig. S1), though S100A9 is also 
known to be produced in microglial cells.
53
Since S100A9 is a highly amyloidogenic protein, the administration of S100A9 amyloid 
species was characterized by amyloid oligomerization in the brain tissues of the S100A9 treated 
animals compared to controls (Fig. 5, S4). The immunopositive staining pattern with A11 amy-
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14
loid oligomeric antibodies was observed in all studied brain areas in the treated mice. It is im-
portant to note, that among the two amyloidogenic polypeptides associated with Alzheimer’s pa-
thology, S100A9 but not Aβ was a major culprit, since Aβ was found only in the blood vessels 
(Fig. 5, S3). Though both Aβ40 and Aβ42 do not form amyloid plaques in wild type mice during 
their life span, Fung et al.
59
 have shown that mouse Aβ40 and Aβ42 are as amyloidogenic as
human Aβ40 and Aβ42 and interspecies Aβ aggregates and fibers are readily formed in vitro. 
These aggregates are also more stable than homogenous human fibers.
59
 The presence of three
amino acid substitutions in the N-terminal part of mouse Aβ do not prevent it from amyloid ag-
gregation and co-aggregation with human counterpart. It was suggested also that mouse Aβ may 
contribute to the amyloid plaque formation in the transgenic mouse, though its quantity is 10-100 
times lower than human Aβ.
59
 In our experiments we have decoupled S100A9 effect on the
mouse brain tissue from the Aβ pathology by using wild type mice and demonstrated that 
S100A9 can induce amyloid oligomerization in the brain tissues by its own (Fig. 5). In wild-type 
aged mice Aβ was found only in the blood vessels of both control and treated animals, possibly 
due to aging, but it was not reactive with amyloid oligomer specific antibodies (Fig. 5). It is also 
notable that amyloid oligomers self-assembled in the mouse brain tissues, due to their inherent 
cytotoxicity, may provide a positive feedback to the elevated cellular stress level exacerbating it 
further. 
Importantly, the elevated cellular levels of S100A9, Bax and activated caspase 3 as well 
as amyloid oligomerization induced in the brain tissues correlated with the behavioral outcome 
disclosed as significantly increased training and decreased retention latencies observed in the 
passive avoidance tests for the S100A9 treated groups (Fig. 6). Remarkably, the effect size in the 
behavioral tests was moderate already in the group treated with native S100A9, while the effect 
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sizes were large in the groups administered both S100A9 amyloid oligomers and fibrils. This in-
dicates that the mouse brains were susceptible to the damaging effect of amyloid species and this 
effect was directly translated into the memory impairments. It is noteworthy that the S100A9 
level in human CSF is already perturbed at the stage of mild cognitive impairment, long preced-
ing Alzheimer’s disease development, sizeable Alzheimer’s-related plaque formation and neu-
ronal loss.
50
 The present results indicate that the cellular stress and amyloid oligomerization in-
duced by S100A9 could be important factors triggering the memory impairment in wild type 
mouse model lacking amyloid plaques. 
In conclusion, intranasal administration of S100A9 native and amyloid species induced 
significant stress responses along with amyloid oligomerization not only locally, but across dis-
tant areas of the brain tissues, which ultimately interfered with mouse behavior, provoking sig-
nificant memory impairment in the passive avoidance test. Since both the tissue and behavioral 
responses occurred without any noticeable involvement of Aβ amyloid aggregation typical of 
Alzheimer’s disease, this may well signify a critical role of proinflammatory and amyloidogenic 
S100A9 protein in eliciting Alzheimer’s-like pathology and symptoms. It might be further postu-
lated that inflammatory pathways and S100A9 in particular can be used as prospective targets for 
therapeutic interventions aimed at allaying neurodegenerative and neuroinflammatory processes 
at a very early stage. In addition, nasal administration of S100A9 species proved to be a compel-
ling method for studying the brain dysfunctions induced by biologically active compounds with 
amyloid properties, whilst possessing the advantages of being noninvasive and easy to apply. 
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Materials and Methods 
S100A9 and its amyloid species  
S100A9 was expressed in E coli and purified as described previously.
60
 Its concentration was 
determined by measuring optical absorbance at 280 nm. The extinction coefficient was ε280 = 
0.53 (mg/ml)
−1
 cm
−1
.
S100A9 amyloid species were produced upon incubation at 2 mg/ml concentration in 
PBS buffer, pH 7.4 and 37 
o
C, using continuous agitation at 600 rpm (Eppendorf Thermomixer
Compact). The specimens containing predominantly amyloid oligomers were collected after 2 h 
incubation and the fibrillar species were produced after 24 h. Subsequently, both S100A9 oligo- 
meric and fibrillar samples were lyophilized. They were reconstituted in PBS buffer directly pri- 
or administration to mice. 
Thioflavin T fluorescence assay 
Thioflavin-T fluorescence assay was performed by adding 20 µM thioflavin-T to S100A9 solu- 
 ions kept on ice and then pipetted into 96-well plates. Thioflavin-T fluorescence was measured 
by a Tecan F200 Pro plate reader, using an excitation filter at 450 nm and an emission filter at 
490 nm. 
AFM imaging 
AFM imaging was carried out by a BioScope Catalyst AFM (Bruker) in the peak force mode in 
air at a resolution of 256 x 256 pixels. Amyloid samples were deposited on the surface of a fresh- 
ly cleaved mica (Ted Pella) for 15 min, washed 3 times with 100 µl deionized water, dried at 
room temperature and then subjected to AFM analysis.
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Subjects 
Fifty-six adult male C57Bl/6 mice were subjected to experimental procedures. The animals were 
ca. 12-month-old and weighted 31.1 ± 1.0 g. The animals were group-housed on a 12:12 light-
dark cycle at 21 
o
C and 50% humidity with access to food and water ad libitum.
Dosing protocol 
Mice were divided into 4 groups of 14 animals per group for 14-day intranasal dosing protocol.
29, 
31
 The control group was administered 8 µl saline vehicle daily and the 3 experimental groups 
received 8 µl saline solution containing 15.0 µg (0.48 mg/kg daily dose) of the following 
S100A9 species: (1) native protein, (2) amyloid oligomers and (3) amyloid fibrils. On comple-
tion of the 14-day protocol (i.e. on days 15-16), all animal groups underwent behavioral testing. 
The next day (i.e. on day 17) after these procedures animals were sacrificed and their brain tis-
sues were fixed in fresh cold 4% paraformaldehyde in PBS, dehydrated in ethanol, cleared in 
toluene and embedded in paraffin for subsequent immunohistochemical analyses.
Behavioral test 
One-trail step-through passive avoidance test was carried out after training in a PACS-30 two-
way shuttle box (Columbus Instruments) as described previously.
61, 62
 The apparatus consisted of
a rectangular chamber divided into two compartments. One compartment was lit by an overhead 
light stimulus, while the other remained in darkness. They were separated by an automatic guil-
lotine door and each compartment had a grid floor, through which foot-shock could be delivered. 
Mouse memory was assessed by the time for a performance measure to occur, i.e. in latency. In 
our experiments latencies corresponded to the times required for animals to enter a dark com-
partment. Briefly, each individual animal was initially introduced into the light compartment. 
During a habituation period, mice were allowed to freely explore the box for 5 min with an open 
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inter-compartment door and subsequently they were returned to their home cage. On the training 
day, each animal was placed into the lit compartment facing away from the dark one and allowed 
to explore it for 30 s. The guillotine door was then lifted and upon animal entry into the dark 
compartment with all four paws plus the tail the guillotine door was closed. The entry time was 
recorded from the time when the door was lifted. The entry time on the training day or a training 
latency (t1) was measured. Following a period of 3 s after guillotine door closure, an inescapable 
foot-shock of 0.5 mA and 3 s duration was delivered and 30 s later each mouse was removed to 
its home cage. Animals, which did not enter the dark compartment within 180 s, underwent an-
other session of training on the same day. The same test was carried out 24 h after passive avoid-
ance training and the one-trail step-through latency defined as a retention latency (t2) was record-
ed. An increase in training latency and decline in retention latency signified impaired memory in 
the task.
61, 62
Immunohistochemistry 
Paraffin embedded mouse brain tissues were microtome sectioned to 3-4 µm thick slices. Single 
and sequential immunohistochemistries on the same tissue sections were performed as described 
previously 
63
 with some modifications.
64
 The following primary antibodies were used: Aβ
(mouse monoclonal, ab11132, 1 in 100, Abcam), S100A9 (rabbit polyclonal, sc-20173, 1 in 100, 
Santa Cruz Biotechnology), A11 (rabbit polyclonal, 1 in 200, gift from Professor Rakez Kayed 
57
), NeuN (mouse monoclonal, MAB377, 1 in 100, Millipore), activated caspase 3 (rabbit poly-
clonal, ab13847, 1 to 50, Abcam) and Bax (rabbit polyclonal, sc-526, 1 to 100, Santa Cruz Bio-
technology). Anti-mouse (MP-7402) and anti-rabbit (MP-7401) IgG peroxidase reagent kits 
(Vector Laboratories) were used as secondary antibodies. The tissues were scanned by using a 
Pannoramic SCAN slide scanner 250 (3D Histech). 
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Cell counting  
Immunopositive cells were counted in 6 randomly selected circular regions (1 mm diameter 
each) in the frontal lobe, hippocampus and cerebellum, respectively, in 6 mouse brain tissues per 
group by using a Pannoramic Viewer (3DHistech Ltd). The cell counts were presented by box-
plots with corresponding data points.
Data analysis  
Statistical data analysis was performed by using a Wolfram Mathematica 11 package. Since there 
were deviations (Shapiro-Wilk test) from the normal distribution in all data sets, non-parametric 
methods such as Mann-Whitney test and bootstrap were applied as major statistical tools.
65, 66
We used the combination of the standardized effect size and associated confidence intervals to 
assess: (1) the magnitude of an effect of interest, i.e. the changes in the training or retention la-
tencies, respectively, in S100A9 treated groups compared to controls and (2) the precision of the 
estimate of such changes. Such approach enables us to conclude on the biological importance of 
the observed effects, rather than merely resorting to statistical significance defined by p values.
44
Cliff’s delta was used as a measure of the effect size due to non-normality of the data dis-
tributions.
45
 Its 95% confidence intervals were calculated by a non-parametric version of correct-
ed and accelerated bootstrap method with 10000 replications.
65, 66
Ethics statement 
All experimental procedures were carried out in accordance with the National Institute of Health 
Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996) 
and the European Communities Council Directive of 24 November 1986 (86/609/EEC) for care 
and use of laboratory animals. They were also approved by the Animal Care and Use Committee 
of the P.K. Anokhin Institute of Normal Physiology, Russian Academy of Medical Science. 
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Supporting information 
Four figures showing (1) representative sequential immunohistochemistry with S100A9 and 
NeuN antibodies of S100A9 treated mouse brain tissues; (2) immunostaining of the mouse brain 
tissues with activated caspase 3 antibodies; (3) sequential immunohistochemistry with S100A9 
and activated caspase-3 antibodies of S100A9 treated mouse brain tissues and (4) sequential im-
munohistochemistry with Aβ, A11 and 100A9 antibodies of control mouse brain tissues.   
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Figure captions 
Fig. 1. Characterization of S100A9 amyloid species. 
(A, B) AFM height images of S100A9 amyloid oligomers and fibrils, respectively. Size of each 
image is 1 µm x 1 µm. (C) Kinetics of S100A9 amyloid formation monitored by thioflavin-T 
fluorescence assay. 
Fig. 2. Immunohistochemical analysis of mouse brain tissues with S100A9 antibodies. 
Representative immunochemistry with S100A9 antibodies of the brain tissues of animal adminis-
tered saline vehicle is shown in the first row (A-F), native S100A9 – in second row (G-L), 
S100A9 oligomeric species – in third raw (M-R)  and S100A9 fibrils in forth raw (S-X), respec-
tively (rows were counted from top to bottom). Immunohistochemistry of the frontal lobe is 
shown in the columns 1, 2; hippocampus – in the columns 3, 4 and cerebellum – in the columns 
5, 6, respectively (columns were counted from left to right). The broad areas of hippocampus, 
frontal lobe, and cerebellum are presented in the columns 1, 3, 5 from left to right (with 200 µm 
scale bars) and the corresponding magnified areas  –  in the columns 2, 4, 6 from left to right 
(with 50 µm. scale bars). Blue color corresponds to Mayer’s hematoxylin staining and red-brown 
color – to S100A9 antigen staining. 
Fig. 3. Immunohistochemical analysis of mouse brain tissues with Bax antibodies. 
Designation of sub-figures and color presentations are as in Fig. 2. 
Fig. 4. Quantification of S100A9, Bax and activated caspase-3 immunopositive cells in 
mouse brain tissues. 
Quantification of immunopositive cells reactive with S100A9 (A-C), Bax (D-F) and activated 
caspase-3 (G-I) antibodies, respectively. Counts of immunopositive cells per mm
2
 are shown
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along y-axis. Counts of immunopositive cells in the frontal lobe are shown in the left column (A, 
D, G), in the hippocampus – in the central column (B, E, H) and in the cerebellum – in the right 
column (C, F, I), respectively. Data are presented by box-plots with the corresponding data 
points per each animal; central line represents median and whiskers – q1 and q4 quartiles. Outli-
ers are shown by black dots. Cell counts in the control group are shown in red, in the group treat-
ed with native S100A9 – in blue, in the group treated with oligomeric S100A9 – in yellow and in 
the group treated with fibrillar S100A9 – in green. *p < 0.05 is compared to control group. 
Fig. 5. Localization of Aβ, S100A9 and amyloid oligomers in mouse brain tissues. 
Immunohistochemistry with Aβ (A, E, I), A11 (B, F, J) and S100A9 (C, G, K) antibodies, re-
spectively, of the brain tissues of mouse administered S100A9 fibrils. Immunohistochemistry of 
the frontal lobe tissues is shown in (A-D); hippocampus – in (E-H) and cerebellum – in (I-L), 
respectively. Superposition of corresponding immunostainings in pseudo-colors (D, H, L): 
S100A9 staining is shown in green, A11– in yellow and Aβ – in orange. Scale bar is 50 µm. 
Fig. 6. Effects of S100A9 species administration on mouse behavior in passive avoidance 
test. 
(A) First day training latencies (t1), (B) second day retention latencies (t2) and (C) effect sizes
(Cliff’s delta) for training and retention latencies in passive avoidance test.  The values of laten-
cies are presented by box-plots with the corresponding data points; central line represents median 
and whiskers represent q1 and q4 quartiles. Outliers are shown by black dots. Data points corre-
sponding to the control group are shown in red, to the group treated with native S100A9 – in 
blue, to the group treated with oligomeric S100A9 – in yellow and to the group treated with fi-
brillar S100A9 – in green. *p < 0.05. 
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